Septerna, Inc. (SEPN)
NASDAQ: SEPN · Real-Time Price · USD
26.76
+0.60 (2.29%)
Dec 5, 2025, 4:00 PM EST - Market closed
Septerna Employees
Septerna had 75 employees as of December 31, 2024.
Employees
75
Change
n/a
Growth
n/a
Revenue / Employee
$293,933
Profits / Employee
-$784,120
Market Cap
1.20B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SEPN News
- 10 days ago - Septerna to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 11 days ago - Septerna's Novo Partnership Begins To Transform The Story - Seeking Alpha
- 25 days ago - Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Septerna to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors - GlobeNewsWire
- 3 months ago - Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases - GlobeNewsWire
- 4 months ago - Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside - Benzinga